Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -6.27%7.55B | 17.91%8.02B | 19.48%7.48B | 10.24%28.45B | -11.83%7.7B | 35.94%8.05B | 23.35%6.8B | -0.84%6.26B | 31.77%25.8B | 41.24%8.73B |
| Total premiums earned | 4.85%6.82B | 7.66%6.4B | 1.08%6.15B | 13.25%24.87B | 11.41%6.33B | 13.61%6.5B | 10.28%5.95B | 17.97%6.09B | 8.73%21.96B | 7.07%5.68B |
| -Net premiums written | 4.85%6.82B | 7.66%6.4B | 1.08%6.15B | 13.25%24.87B | 11.41%6.33B | 13.61%6.5B | 10.28%5.95B | 17.97%6.09B | 8.73%21.96B | 7.07%5.68B |
| Net investment income | -57.41%599.8M | 838.70%1.39B | 178.53%513.5M | -123.27%-483.8M | -344.93%-2.06B | 463.32%1.41B | 294.47%147.8M | -165.82%-653.9M | 182.37%2.08B | 319.55%842.4M |
| Net realized gain loss on investments | -43.47%-173.6M | -564.18%-435.4M | -8.87%542.6M | 1,296.76%1.55B | 166.90%1.66B | 37.63%-121M | 135.25%93.8M | 367.84%595.4M | -114.12%-129.6M | -24.70%622M |
| Interest income | 15.56%303M | 8.52%666.3M | 16.72%270.2M | 32.47%2.51B | 11.75%1.77B | 82.97%262.2M | 32.16%614M | -39.45%231.5M | 90.57%1.9B | 332.25%1.58B |
| Total expenses | -8.77%5.98B | 12.53%6.07B | 21.32%6.31B | 14.64%22.81B | -14.33%6.02B | 47.98%6.56B | 17.96%5.39B | 14.52%5.2B | 35.54%19.89B | 122.79%7.03B |
| Loss adjustment expense | -6.20%6.14B | 10.75%5.99B | 19.24%6.09B | 11.20%22.88B | -13.27%6.18B | 41.43%6.55B | 10.18%5.41B | 11.36%5.1B | 26.74%20.57B | 60.58%7.13B |
| Fees and commission expense | --0 | ---- | --0 | ---- | ---- | --0 | ---- | --0 | ---- | ---- |
| Selling general and administration | 28.31%1.66B | ---- | 48.35%1.82B | ---- | ---- | -4.97%1.29B | ---- | --1.23B | ---- | ---- |
| -General and administrative expense | 32.82%377.2M | ---- | 91.47%480.2M | ---- | ---- | -25.77%284M | ---- | --250.8M | ---- | ---- |
| -Selling and marketing expense | 27.04%1.28B | ---- | 37.27%1.34B | ---- | ---- | 3.19%1.01B | ---- | --975.6M | ---- | ---- |
| Net non operatingInterest income (expenses) | -29.62%-213.1M | -29.30%-207.4M | -25.68%-190.4M | -27.25%-649M | -32.34%-172.7M | -31.73%-164.4M | -23.01%-160.4M | -21.88%-151.5M | -12.63%-510M | -3.82%-130.5M |
| -Interest expense-non operating | 29.62%213.1M | 29.30%207.4M | 25.68%190.4M | 27.25%649M | 32.34%172.7M | 31.73%164.4M | 23.01%160.4M | 21.88%151.5M | 12.63%510M | 3.82%130.5M |
| Income from associates and other participating interests | 17.22%305M | -40.97%130.7M | 0.70%128.6M | -6.45%956.3M | 171.73%347M | -10.74%260.2M | -17.76%221.4M | -61.74%127.7M | -0.02%1.02B | -50.58%127.7M |
| Special income (charges) | ---- | ---- | ---- | --0 | --0 | --0 | --0 | ---- | -54.92%549.8M | -75.25%290.7M |
| -Less:Other special charges | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 54.92%-549.8M | 75.25%-290.7M |
| Other Operating costs | -45.64%-1.72B | -104.27%-1.8M | -43.77%-1.65B | -38.11%237.9M | -10.21%3.72B | 14.84%-1.18B | -27.12%42.2M | -771.50%-1.15B | 62.88%384.4M | 19,912.08%4.14B |
| Income before tax | 4.73%1.56B | 38.46%1.95B | 10.38%1.17B | -4.57%5.64B | -1.53%1.68B | 0.18%1.49B | 49.40%1.41B | -40.30%1.06B | 20.47%5.91B | -43.73%1.7B |
| Income tax | -14.85%318.9M | -0.93%352.1M | -25.73%212.7M | 69.12%1.38B | 1,160.70%359.3M | 23.07%374.5M | 207.71%355.4M | -21.56%286.4M | -25.55%813.4M | -94.78%28.5M |
| Earnings from equity interest net of tax | ||||||||||
| Net income | 11.27%1.25B | 51.72%1.6B | 23.81%953M | -16.33%4.26B | -21.31%1.32B | -5.69%1.12B | 27.34%1.06B | -45.18%769.7M | 33.66%5.09B | -32.49%1.67B |
| Net Income continuous operations | 11.27%1.25B | 51.72%1.6B | 23.81%953M | -16.33%4.26B | -21.31%1.32B | -5.69%1.12B | 27.34%1.06B | -45.18%769.7M | 33.66%5.09B | -32.49%1.67B |
| Noncontrolling interests | 5.98%94M | 17.66%165.2M | 207.35%7.3M | -45.59%388M | -52.15%165.7M | -24.89%88.7M | 48.26%140.4M | -104.42%-6.8M | 62.99%713.1M | 112.71%346.3M |
| Net income attributable to the company | 11.73%1.15B | 56.95%1.44B | 21.79%945.7M | -11.57%3.87B | -13.27%1.15B | -3.56%1.03B | 24.65%915.4M | -37.88%776.5M | 29.86%4.38B | -42.69%1.33B |
| Preferred stock dividends | -2.21%48.6M | 9.96%49.7M | ||||||||
| Other under preferred stock dividend | -53.5M | |||||||||
| Net income attributable to common stockholders | 11.73%1.15B | 56.95%1.44B | 21.79%945.7M | -10.44%3.88B | -9.52%1.16B | -3.56%1.03B | 24.65%915.4M | -37.88%776.5M | 30.13%4.33B | -43.74%1.28B |
| Diluted earnings per share | 21.42%55.9 | 65.11%66.34 | 38.60%46.1 | -7.20%173.41 | -4.49%54.46 | 0.92%46.04 | 29.20%40.18 | -37.45%33.26 | 32.69%186.87 | -32.19%57.02 |
| Basic earnings per share | 22.10%52.04 | 65.71%61.61 | 38.55%42.7 | -7.32%160.56 | -4.63%50.42 | 0.85%42.62 | 29.10%37.18 | -37.59%30.82 | 31.87%173.24 | -32.50%52.87 |
| Dividend per share | 0 | 0 | 0.00%15 | 50.00%15 | 0 | 0 | 0 | 50.00%15 | 0.00%10 | 0 |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.